Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scilex Holding Company ( (SCLX) ) has shared an announcement.
On June 23, 2025, Scilex Holding Company announced the deferral of the record date for its previously announced dividend of Series 1 Mandatory Exchangeable Preferred Stock from May 2, 2025, to a future date yet to be determined by the Board of Directors. This decision allows the Board to retain flexibility in determining the new record date and potentially revoking the dividend, impacting stakeholders by introducing uncertainty regarding the timing and payment of the dividend.
The most recent analyst rating on (SCLX) stock is a Buy with a $245.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company is a revenue-generating company focused on developing and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. Their commercial products include ZTlido®, ELYXYB®, and Gloperba®, and they have several product candidates in development, including SP-102, SP-103, and SP-104.
Average Trading Volume: 136,059
Technical Sentiment Signal: Sell
Current Market Cap: $34.13M
See more data about SCLX stock on TipRanks’ Stock Analysis page.